Cyto-Sen Therapeutics, Inc., a biopharmaceutical firm, specializes in developing natural killer cells using a particle-based expansion and activation method for cancer treatment. The company creates cellular immunotherapeutics for personalized and universal donor sources to combat various forms of cancer. Established in 2014, Cyto-Sen Therapeutics, Inc. is headquartered in Orlando, Florida. It has formed a strategic alliance with KBI Biopharma and currently operates as a subsidiary of Kiadis Pharma N.V. since June 6, 2019.